Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etravirine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etravirine SCHEMBL28640238 | 0.99 | CYP2C9 (0.98) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL3219153 | 0.99 | CYP2C9 (0.98) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL14439966 | 0.94 | CYP2C9 (0.89) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL1085342 | 0.94 | CYP2C9 (0.88) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL1085387 | 0.92 | CYP2C9 (0.85) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL1085485 | 0.91 | CYP2C9 (0.83) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1085572 | 0.91 | CYP2C9 (0.83) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1183658 | 0.90 | CYP2C9 (0.81) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL1085575 | 0.88 | CYP2C9 (0.77) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL247490 | 0.88 | CYP2C9 (0.78) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12840 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4719485-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Taimed Biologics Inc. (TW) | 2026-04-08 | — | — | EP | claimed |
| EP-1505980-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | Tibotec Pharmaceuticals Ltd. (IE) | 2005-02-16 | — | — | EP | claimed |
| WO-2004050058-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | claimed |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | US | claimed |
| WO-2003094920-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-20 | — | — | WO | claimed |
| EP-1214300-B1 | RATE-CONTROLLED PARTICLES | ABBOTT GMBH & CO KG (DE) | 2003-09-03 | — | — | EP | claimed |
| JP-2003518012-A | — | — | 2003-06-03 | — | — | JP | claimed |
| EP-1002795-B1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-05 | — | — | EP | claimed |
| EP-1270560-A1 | Hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | claimed |
| EP-1214300-A2 | RATE-CONTROLLED PARTICLES | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-06-19 | — | — | EP | claimed |
| WO-2001023362-A2 | RATE-CONTROLLED PARTICLES | ABBOTT GMBH & CO. KG (DE) | 2001-04-05 | — | — | WO | claimed |